GSK gets US green light for two-drug HIV treatment

9th Apr 2019 07:29

(Sharecast News) - GlaxoSmithkline said its two drug HIV treatment had been granted US market approval.The pharmaceutical company said on Tuesday the US Food and Drug Administration (FDA) had approved Dovato, a combination of dolutegravir and lamivudine, for the treatment of adults with no antiretroviral treatment history.The drug is made by GSK's HIV drugs unit ViiV Healthcare, in which Pfizer and Shionogi also have a stake.Viiv chief executive Deborah Waterhouse said Dovato would help patients "treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment".